Safety and Immunogenicity Of A Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered In Healthy Meningococcal Vaccine-Naïve Children (2-9 Years)

Background MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine that contains tetanus toxoid as carrier protein. The vaccine is intended for global use in individuals 6 weeks of age and older. We evaluated the safety and immunogenicity of MenACYW-TT compared to a licensed quadrivalent conjugate meningococcal vaccine ( MenACWY-CRM [Menveo®]) in US children 2-9 years of age. Methods In …